Momelotinib therapy for myelofibrosis: a 7-year follow-up

One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Cancer J
Main Authors: Tefferi, Ayalew, Barraco, Daniela, Lasho, Terra L., Shah, Sahrish, Begna, Kebede H., Al-Kali, Aref, Hogan, William J., Litzow, Mark R., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Pardanani, Animesh
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5841331/
https://ncbi.nlm.nih.gov/pubmed/29515114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0067-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki